



THIONATION OF AN ANTITUMOUR CYCLIC PENTAPEPTIDE, ASTIN B, FROM ASTER TATARICUS¹⁾

Hiroshi Morita, Shinji Nagashima, Koichi Takeya and Hideji Itokawa*

Department of Pharmacognosy, School of Pharmacy, Tokyo University of Pharmacy and
Life science, Horinouchi 1432-1, Hachioji, Tokyo 192-03, Japan

Abstract: Astin B, an antitumour cyclic pentapeptide, isolated from the roots of *Aster tataricus*, was thionated with Lawesson's reagent to give [Ser-3-ψ(CS-NH)-β-Phe-4]astin B (thioastin B). NMR spectroscopy showed that S atom was introduced at Ser³. The conformation of thioastin B was studied by NOE experiments, temperature effects on NH protons and vicinal NH-Cα coupling constants. Thioastin B was shown to retain the restricted bioactive conformation of astin B and had a more promising antitumour activity than astin B.

Antitumour cyclic pentapeptides, astins, containing two chlorine atoms, were originally isolated from the roots of *Aster tataricus* (Compositae), and their structures²⁾ and conformation³⁾ were investigated by high field NMR, X-ray and MD simulation studies. Astins, containing one chlorinated proline, has a conformation different from that of an analogous cyclic peptide, cyclochlorotine⁴⁾ isolated from *Penicillium islandicum* Sopp, and the unique structure stimulated us to derive the analogue with higher potency.

Recently, various procedures have been reported on modification of structures and conformations of peptide backbones. Such changes may also modify the biological properties of active peptides. Of them, substitution of a sulfur atom for the oxygen atom seems to be a highly isosteric replacement. Since thionation can strongly influence the secondary structure of cyclic peptides, it may provide us with valuable information about conformational structure-activity relationships of bioactive peptides.⁵⁾

In the present communication, astin B (1) having a potent antitumour activity, was thionated with Lawesson's reagent,⁶⁾ to produce thioastin B (2) having a more promising antitumour activity, and the structure and conformation of thioastin B (2) were studied by NMR spectroscopy.

Thionation of cyclic peptides with Lawesson's reagent often give complicated mixture of products.⁵⁾ However, in the case of astin B, use 2 mol equiv. of Lawesson's reagent in dry dioxane at 50°C for 12 h, gave a single major product, thioastin B.⁷⁾

Thioastin B (2), mp. 178 - 180 °C, [α]_D²⁵ -115.8° (c 0.19, MeOH), showed a quassimolecular ion (M+H)⁺ by FAB-MS spectrum, corresponding to the molecular formula, C₂₅H₃₃N₅O₆SCl₂.⁸⁾ The assignments of ¹H and ¹³C-NMR signals of 2 were made by the combination of ¹H-¹H COSY, HMQC⁹⁾ and HMBC¹⁰⁾ spectra

(Table 1). The position of the mono thionated carbonyl group was determined by NMR spectroscopy. In the ^1H NMR spectrum (DMSO-d_6) of thioastin B, the $\beta\text{-Phe-NH}$ signal (δ 9.38) was in a considerably lower field than that (δ 7.38) in astin B, and the chemical shift of carbonyl carbon of Ser^3 was observed at δ 199.51. Therefore, the structure of thioastin B was determined to be [Ser-3- ψ (CS-NH)- $\beta\text{-Phe-4}$]astin B.

Thionation is a useful method for modification of peptides for conformation-activity investigations.⁵⁾ We have already reported about the solution conformation of astin B³⁾ and that the activities of astins are influenced by the conformations.¹¹⁾ Therefore, we analyzed the conformational changes introduced by thionation into astin B and compared the conformation of thioastin B, showing more promising activity than astin B, with that of astin B.

The first step in the determination of the secondary structure of cyclic peptides in solution by NMR is to distinguish the NH protons exposed to the solvent or shielded from the solvent either sterically or through hydrogen bonding. The most common procedure for that is to determine the temperature effects on the NMR signals of NH protons.¹²⁾ The temperature coefficients ($d\delta/dT$) of thioastin B (Table 2) clearly suggest that $\text{Ser}^3\text{-NH}$ and $\beta\text{-Phe}^4\text{-NH}$ are involved

Table 1. ^1H and ^{13}C -NMR chemical shifts of thioastin B (2)

	proton	carbon
Pro(Cl₂)¹		
α	4.87 (d, 5.3)	64.51
β	5.12 (t, 5.3)	65.18
γ	4.77 (m)	54.83
δ	3.35 (m)	51.06
	4.34 (m)	
$\text{C}=\text{O}$		166.35
allo Thr²		
α	4.25 (t, 9.4)	57.04
β	4.20 (m)	65.76
γ	5.79 (d, 5.9; OH)	
NH	1.22 (d, 5.6)	21.83
$\text{C}=\text{O}$	8.38 (d, 9.4)	
		169.79
Ser³		
α	4.36 (m)	65.39
β	3.73 (br s)	62.16
NH	8.88 (d, 4.1)	
$\text{C}=\text{O}$		199.51
$\beta\text{-Phe}^4$		
α	2.39 (t, 12.5)	42.43
β	2.89 (dd, 4.7, 12.5)	56.90
γ	5.52 (m)	140.91
δ		126.03
ϵ	7.22 - 7.31 (m)	128.18
ζ		126.73
NH	9.38 (d, 7.3)	
$\text{C}=\text{O}$		170.71
Abu⁵		
α	4.27 (td, 3.9, 9.3)	53.34
β	1.47 (m)	22.64
	1.73 (m)	
γ	0.95 (t, 7.4)	10.50
NH	8.62 (d, 3.9)	
$\text{C}=\text{O}$		172.26

Measurements were performed in DMSO-d_6 at 500 MHz (^1H) and 125 MHz (^{13}C).




Fig. 1. Structures of astin B (1: $\text{R}=\text{O}$) and thioastin B (2: $\text{R}=\text{S}$); Pro in 1 was provisionally numbered as the first amino acid.




Fig. 2. A stereostructure of thioastin B; The bold dashed lines indicate the strong intramolecular hydrogen bonds and normal dashed line the weak one. The arrows show the NOE relationships in DMSO-d_6 .

Table 2. Temperature coefficients, $-d\delta/dT$ (10^3 ppm/K), of NH chemical shifts of astin B (1) and thioastin B (2) in DMSO- d_6 .

compounds	<i>allo</i> Thr ²	Ser ³	β -Phe ⁴	Abu ⁵
astin B	3.0	2.2	2.8	4.5
thioastin B	3.7	1.7	1.7	4.0

Table 3. Backbone dihedrals (ϕ) in astin B (1) and thioastin B (2), calculated from vicinal NH-C α H coupling constants (Hz).

Residues	astin B (1)		thioastin B (2)	
	Hz	ϕ angle [*]	Hz	ϕ angle [*]
<i>allo</i> Thr ²	9.4	-97	9.4	-97
Ser ³	4.2	-66	4.1	-65
β -Phe ⁴	6.8	-160	7.3	-157
Abu ⁵	3.7	-63	3.9	-64

* Calculated by using the Karplus-Bystrov equation: $^3J_{\text{HN}\alpha} = 9.4\cos^2|60-\phi| - 1.1\cos|60-\phi| + 0.4$

in intramolecular hydrogen bonds, because the coefficients of Ser³ and β -Phe⁴ were lower than those in the active conformer of astin B. The temperature coefficient of the NH in *allo*Thr² was higher than that in astin B. Therefore, formation of stable hydrogen bonds between *allo*Thr²-O and Ser³-NH, and between β -Phe⁴-NH and β -Phe⁴-CO was implied.

The allowed dihedral angles were calculated from the vicinal NH-C α H coupling constants obtained by ¹H NMR spectrum, by Karplus type equation proposed by Bystrov et al.¹³⁾ The J values and the corresponding calculated dihedral angles, ϕ , are shown in Table 3. The corresponding dihedral angles of the two compounds have about the same values except for that in β -Phe⁴. The calculated ϕ angle in β -Phe⁴ indicates that the thioamide proton orients inside the backbone and the presence of a stronger intramolecular hydrogen bond between β -Phe⁴-CO and β -Phe⁴-NH than in astin B.

Sulfur is a weaker hydrogen bond acceptor than oxygen: the distance of a hydrogen bond between NH and S is about 50 pm longer than that between NH and O in amides, due to its larger covalent and van der Waals radius.¹⁴⁾ The C=O of Ser³ and the corresponding C=S are regarded not to involve in intramolecular hydrogen bonds. In contrast, the amide nitrogen next to the thiocarbonyl group is a stronger hydrogen donor,¹⁵⁾ which is also corresponded to the above results in thioastin B.

The conformation of thioastin B, thus proposed, is illustrated in Fig. 2. This conformation was also supported by ROE relationship in ROESYPH spectrum,¹⁶⁾ which is almost the same as that in astin B.³⁾

The conformational analyses thioastin B resulted in the strong intramolecular hydrogen bond between β -Phe⁴-NH and β -Phe⁴-CO in thioastin B more than that in astin B. The main conformer with 5 \rightarrow 1 and 3 \rightarrow 4 turns may play an important role in its antitumor activity. The biologically active conformation of thioastin B may be retained mainly by the intramolecular hydrogen bond between Ser³-NH and Ser³-OH, which is verified by the fact that the acetylated analog with different conformation from that in astin B, whose intramolecular hydrogen bond was severed by acetylation of Ser-OH, showed less activity.¹¹⁾

From the results of our present studies, substitution of sulfur for amide oxygen at Ser³ in astin B was shown to modify the antitumor activity and backbone conformation of the original compound. Thioastin B possessing the biologically active conformer with rigid backbone showed an antitumor activity on S-180A more promising than astin B.^{17, 18)}

Acknowledgments: The authors thank the Ministry of Education, Science and Culture, Japan, for financial support through Grant-in-Aid for Encouragement of Young Scientists.

References and Notes

1. Cyclic Peptides from Higher Plants. Part 19.
2. H. Morita, S. Nagashima, K. Takeya, and H. Itokawa, *Chem. Pharm. Bull.*, **1993**, *41*, 992; H. Morita, S. Nagashima, K. Takeya, H. Itokawa and Y. Iitaka, *Tetrahedron*, in press.
3. H. Morita, S. Nagashima, K. Takeya, and H. Itokawa, *Tetrahedron*, **1994**, *50*, 11613.
4. H. Yoshioka, K. Nakatsu, M. Sato and T. Tatsuno, *Chem. Lett.*, **1972**, 1319.
5. H. Kessler, A. Geyer, H. Matter and M. Kock, *Int. J. Peptide Protein Res.*, **1992**, *40*, 25.
6. B. S. Pederson, S. Scheibye, N. H. Nilsson and S.-O. Lawesson, *Bull. Soc. Chim. Belg.*, **1978**, *87*, 223; S. Scheibye, B. S. Pederson and S.-O. Lawesson, *ibid.*, **1978**, *87*, 229.
7. A solution of **1** (10 mg, 0.01 mmol) in 1,4-dioxane (2 ml) and Lawesson's reagent (10 mg, 0.03 mmol) were stirred at 50 °C. After 12 h, water (1 ml) was added to the mixture which was left stands for 12 h. The reaction mixture was concentrated to dryness and the residue was chromatographed on alumina with CH₂Cl₂ - MeOH (15 : 1). Finally, reversed phase HPLC using 30 % CH₃CN in H₂O as eluent gave thioastin B (**2**) as a single product (4 mg).
8. HR FAB MS of **1** m/z: 602 ((M+H)⁺, Calcd for C₂₅H₃₄N₅O₆SCl₂ 602.1607, Found 602.1609).
9. A. Bax and S. Subramanian, *J. Magn. Reson.*, **1986**, *67*, 565 .
10. A. Bax and M. F. Summers, *J. Am. Chem. Soc.*, **1986**, *108*, 2093 .
11. 36th SYMPOSIUM on THE CHEMISTRY OF NATURAL PRODUCTS, HIROSHIMA, SYMPOSIUM PAPERS pp 445.
12. H. Kessler, *Angew. Chem.*, **1982**, *94*, 509; *ibid.*, int. Ed., **1982**, *21*, 2547.
13. V. F. Bystrov, V. T. Ivanov, S. L. Portnova, T. A. Balashova and Yu. A. Ovchinnikov, *Tetrahedron*, **1973**, *29*, 873.
14. G. C. Vogel and R. S. Drago, *J. Am. Chem. Soc.*, **1970**, *92*, 5347; A. D. Sherry and K. F. Purcell, *ibid.*, **1972**, *94*, 1848.
15. E. P. Dudek and G. Dudek, *J. Org. Chem.*, **1967**, *32*, 823.
16. A. A. Bothner-By, R. L. Stephens, J. Lee, C. D. Warren and R. W. Jeanloz, *J. Am. Chem. Soc.*, **1984**, *106*, 811.
17. A. Hoshi and K. Kuretani, *Farmacis*, **1973**, *9*, 464.
18. Preliminary assay of *in vivo* antitumor activity was evaluated using Sarcoma 180 ascites in mice. When astin B and thioastin B were administered at 0.5 mg/kg/day for 5 consecutive days, tumor growths were 26 % and 10 %, respectively, of the control.

(Received in Japan 24 January 1995; accepted 13 February 1995)